Biology Reference
In-Depth Information
[31] Juliano RL, Ling V. A surface glycoprotein modulating drug
permeability in Chinese hamster ovary cell mutants. Biochim
Biophys Acta 1976;455(1):152
e
62.
[32] Nooter K, Herweijer H. Multidrug resistance (mdr) genes in human
cancer. Br J Cancer 1991;63(5):663
e
9.
[33] Tsuruo T, et al. Overcoming of vincristine resistance in P388
leukemia in vivo and in vitro through enhanced cytotoxicity of
vincristine and vinblastine by verapamil. Cancer Res 1981;
41(5):1967
e
72.
[34] Bissell MJ, Radisky D. Putting tumors in context. Nat Rev Cancer
2001;1(1):46
e
54.
[35] Harris AL. Hypoxia
e
a key regulatory factor in tumor growth. Nat
Rev Cancer 2002;2(1):38
e
47.
[36] Sharp FR, Bernaudin M. HIF1 and oxygen sensing in the brain. Nat
Rev Neurosci 2004;5(6):437
e
48.
[37] Bingle L, Brown NJ, Lewis CE. The role of tumor-associated
macrophages in tumor progression: implications for new anticancer
therapies. J Pathol 2002;196(3):254
e
65.
[38] Kitano H, Oda K. Self-extending symbiosis: a mechanism for
increasing robustness
[52] Bruchovsky N, et al. Intermittent androgen suppression for prostate
cancer: canadian prospective trial and related observations. Mol
Urol 2000;4(3):191
9. discussion 201.
[53] Shimada T, Aihara K. A nonlinear model with competition
between prostate tumor cells and its application to intermittent
androgen suppression therapy of prostate cancer. Math Biosci
2008;214(1
e
2):134
e
9.
[54] Morohashi M, et al. Robustness as a measure of plausibility in
models of biochemical networks. J Theor Biol 2002;216(1):19
e
30.
[55] Takahashi Y, Nishioka K. Survival without tumor shrinkage: re-
evaluation of survival gain by cytostatic effect of chemotherapy.
J Natl Cancer Inst 1995;87(16):1262
e
3.
[56] Uhr JW, et al. Cancer dormancy: opportunities for new therapeutic
approaches. Nat Med 1997;3(5):505
e
9.
[57] Holmgren L, O'Reilly MS, Folkman J. Dormancy of micro-
metastases: balanced proliferation and apoptosis in the presence of
angiogenesis suppression. Nat Med 1995;1(2):149
e
53.
[58] Murray C. Tumor dormancy: not so sleepy after all. Nat Med
1995;1(2):117
e
8.
[59] Sole RV. Phase transitions in unstable cancer cell populations. Eur
Phys J 2003;B(35):117
e
23.
[60] Dropulic B, Hermankova M, Pitha PM. A conditionally replicating
HIV-1 vector interferes with wild-type HIV-1 replication and
spread. Proc Natl Acad Sci U S A 1996;93(20):11103
e
through evolution. Biol Theory 2006;
1(1):61
e
6.
[39] Pawelek JM. Tumor-cell fusion as a source of myeloid traits in
cancer. Lancet Oncol 2005;6(12):988
e
93.
[40] Pawelek J, et al. Co-opting macrophage traits in cancer progres-
sion: a consequence of tumor cell fusion? Contrib Microbiol
2006;13:138
8.
[61] Weinberger LS, Schaffer DV, Arkin AP. Theoretical design of
a gene therapy to prevent AIDS but not human immunodeficiency
virus type 1 infection. J Virol 2003;77(18):10028
e
55.
[41] Vignery A. Macrophage fusion: are somatic and cancer cells
possible partners? Trends Cell Biol 2005;15(4):188
e
36.
[62] Owen MR, Byrne HM, Lewis CE. Mathematical modelling of the
use of macrophages as vehicles for drug delivery to hypoxic tumor
sites. J Theor Biol 2004;226(4):377
e
91.
[63] Moriya H, Shimizu-Yoshida Y, Kitano H. In vivo robustness
analysis of cell division cycle genes in Saccharomyces cerevisiae.
PLoS Genet 2006;2(7):e111.
[64] Kitano H. A robustness-based approach to systems-oriented drug
design. Nat Rev Drug Discov 2007;6(3):202
e
10.
[65] Yao L, Rzhetsky A. Quantitative systems-level determinants of human
genes targeted by successful drugs. Genome Res 2008;18(2):206
e
13.
[66] Goh KI, et al. The human disease network. Proc Natl Acad Sci U S A
2007;104(21):8685
e
90.
[67] Hase T, et al. Structure of protein interaction networks and their
implications on drug design. PLoS Comput Biol 2009;5(10):
e1000550.
[68] Brynjolfsson E, Smith MD, Hu Y. Consumer Surplus in the Digital
Economy: Estimating the Value of Increased Product Variety at
Online Booksellers. Cambridge, MA: MIT Sloan School of
Management; 2003.
[69] Agoston V, Csermely P, Pongor S. Multiple weak hits confuse
complex systems: a transcriptional regulatory network as an example.
Phys Rev E Stat Nonlin Soft Matter Phys 2005;71(5 Pt 1):051909.
[70] Csermely P, Agoston V, Pongor S. The efficiency of multi-target
drugs: the network approach might help drug design. Trends
Pharmacol Sci 2005;26(4):178
e
93.
[42] Ogle BM, Cascalho M, Platt JL. Biological implications of cell
fusion. Nat Rev Mol Cell Biol 2005;6(7):567
e
75.
[43] Carlson JM, Doyle J. Highly optimized tolerance: a mechanism for
power laws in designed systems. Phys Rev E Stat Phys Plasmas
Fluids Relat Interdiscip Topics 1999;60(2 Pt A):1412
e
27.
[44] Carlson JM, Doyle J. Complexity and robustness. Proc Natl Acad
Sci U S A 2002;99(Suppl. 1):2538
e
45.
[45] Csete ME, Doyle JC. Reverse engineering of biological
complexity. Science 2002;295(5560):1664
e
9.
[46] Kitano H. Violations of robustness trade-offs. Mol Syst Biol
2010;6:384.
[47] Hochhaus A. Cytogenetic and molecular mechanisms of resistance
to imatinib. Semin Hematol 2003;40(2 Suppl. 3):69
e
79.
[48] Hochhaus A, et al. Roots of clinical resistance to STI-571 cancer
therapy. Science 2001;293(5538):2163.
[49] Skipper HE, et al. A quick reference chart on cross resistance
between anticancer patients. Cancer Chemother Rep 1972;56(4):
493
e
8.
[50] Gleave M, et al. Intermittent androgen suppression for prostate
cancer: rationale and clinical experience. Eur Urol 1998;34
(Suppl. 3.):37
e
41.
[51] Gleave ME, et al. Neoadjuvant androgen withdrawal therapy
decreases local recurrence rates following tumor excision in the
Shionogi tumor model. J Urol 1997;157(5):1727
e
30.
82.
e
e
